Greenwich Biosciences' vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Their strategy is to build on their world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. Epidiolex is Greenwich’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. Greenwich’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia.
GW Pharmaceuticals (GW), along with its U.S. subsidiary Greenwich Biosciences, is a pioneering global biopharmaceutical company that has established a world-leading position in cannabinoid science and medicines over the last 20 years. GW’s mission is to transform the lives of seriously ill patients through developing and delivering rigorously tested cannabis-derived pharmaceutical medicines. Our aim is to develop regulatory-approved medicines with documented safety and efficacy profiles that are manufactured to the highest standards. GW’s research efforts initially focused on the unmet needs of patients with Multiple Sclerosis (MS), while in recent years the Company has focused on helping children and adults with severe, life-threatening forms of epilepsy. Looking to the future, GW’s deep scientific knowledge and extensive body of research is enabling the Company to explore new therapeutic areas, including neurology, oncology, psychiatry and autism spectrum disorders. Since the Company was founded in 1998, more than 6,000 patients have been involved in GW’s clinical trials globally. GW has collected more than 80,000 years of human safety data, been featured in more than 80 peer-reviewed publications, and generated high-quality evidence which has appeared in the New England Journal of Medicine and The Lancet. In 2018, TIME magazine named GW one of the 'Top 50 Genius Companies of 2018 That Are Inventing the Future' in recognition of this work.
Greenwich Biosciences / GW Pharmaceuticals
HQ: Carlsbad, California
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.